The Sleegers Lab decodes why some brains develop Alzheimer’s while others stay resilient, and turns those insights into early, low-burden biomarkers. 

We pair population-scale genomics with single-cell and long-read transcriptomics, powered by rich cohorts and a modern biobank, to enable earlier, more precise care.